SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada
GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CNS) disorders and oncology, and the first and only Korean company to independently develop and commercialize a new drug in the U.S., today announced more than 100,000 patients have been treated globally with cenobamate, an anti-seizure medication (ASM) developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc.
- In the U.S., cenobamate is marketed under the brand name XCOPRI® (cenobamate tablets) CV.
- Since 2023, Dexcel Pharma, an international specialty pharmaceutical company, has been marketing cenobamate in Israel, and Paladin Labs Inc., launched cenobamate in Canada.
- "This cenobamate milestone coincides with the completion earlier this year of SK Biopharmaceuticals' strategic Global Partnering plan.
- "We are excited to continue transforming the landscape of epilepsy care with innovative treatment options and to advocate for epilepsy as a priority for healthcare systems across Europe."